Safety and Efficacy of a Recombinant Hepatitis E Vaccine
Top Cited Papers
- 1 March 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (9) , 895-903
- https://doi.org/10.1056/nejmoa061847
Abstract
Hepatitis E virus (HEV) is an important cause of viral hepatitis. We evaluated the safety and efficacy of an HEV recombinant protein (rHEV) vaccine in a phase 2, randomized, double-blind, placebo-controlled trial.Keywords
This publication has 15 references indexed in Scilit:
- Hepatitis E VaccinesDrugs, 2004
- Hepatitis E virusReviews in Medical Virology, 2003
- Perspectives of Vaccination against Hepatitis EIntervirology, 2001
- Hepatitis E: An Emerging Infectious DiseaseEpidemiologic Reviews, 1999
- Association of hepatitis E virus with an outbreak of hepatitis at a military training camp in NepalJournal of Medical Virology, 1998
- Recombinant vaccine against hepatitis E: dose response and protection against heterologous challengeVaccine, 1997
- Rates of Hepatitis E Virus Infection and Disease among Adolescents and Adults in Kathmandu, NepalThe Journal of Infectious Diseases, 1997
- Phylogenetic analysis of the calicivirusesJournal of Medical Virology, 1997
- Epidemiology of hepatitis E virus infectionJournal of Viral Hepatitis, 1997
- Hepatitis viruses: changing patterns of human disease.Proceedings of the National Academy of Sciences, 1994